Cargando…

Monocyte/HDL Cholesterol Ratios as a New Inflammatory Marker in Patients with Schizophrenia

Purpose: Monocyte/HDL cholesterol ratio (MHR) is a novel inflammatory marker that is used as a prognostic factor for cardiovascular diseases and has been studied in many diseases. The aim of this study was to investigate the role of inflammatory factors in schizophrenia patients by examining MHR lev...

Descripción completa

Detalles Bibliográficos
Autores principales: Kılıç, Nülüfer, Tasci, Gulay, Yılmaz, Seda, Öner, Pınar, Korkmaz, Sevda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958934/
https://www.ncbi.nlm.nih.gov/pubmed/36836510
http://dx.doi.org/10.3390/jpm13020276
_version_ 1784895148043272192
author Kılıç, Nülüfer
Tasci, Gulay
Yılmaz, Seda
Öner, Pınar
Korkmaz, Sevda
author_facet Kılıç, Nülüfer
Tasci, Gulay
Yılmaz, Seda
Öner, Pınar
Korkmaz, Sevda
author_sort Kılıç, Nülüfer
collection PubMed
description Purpose: Monocyte/HDL cholesterol ratio (MHR) is a novel inflammatory marker that is used as a prognostic factor for cardiovascular diseases and has been studied in many diseases. The aim of this study was to investigate the role of inflammatory factors in schizophrenia patients by examining MHR levels and to compare schizophrenia patients and healthy controls in terms of cardiovascular disease risk. Method: A total of 135 participants between the ages of 18–65, 85 diagnosed with schizophrenia, and 50 healthy individuals in the control group were included in this cross-sectional study. Venous blood samples were taken from the participants and CBC parameters and lipid profiles were analyzed. The sociodemographic and clinical data form and positive and negative symptoms scale (PANSS) were administered to all participants. Results: Although monocyte levels were significantly higher in the patient group, HDL-C levels were lower at significant levels. MHR was found to be higher in the patient group compared to the control group at significant levels. When compared to the control group, total cholesterol, triglyceride, WBC, neutrophil, basophil, and platelet levels were higher in the patient group at significant levels, and RBC, hemoglobin, and hematocrit levels were significantly lower. Conclusion: The elevated MHR in patients with schizophrenia may contribute to our understanding that inflammation plays important roles in the pathophysiology of schizophrenia. Additionally, knowing the levels of MHR and considering the recommendations, such as diet and exercise, in the treatment approaches made us think that it might be beneficial in protecting schizophrenia patients against cardiovascular diseases and early death.
format Online
Article
Text
id pubmed-9958934
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99589342023-02-26 Monocyte/HDL Cholesterol Ratios as a New Inflammatory Marker in Patients with Schizophrenia Kılıç, Nülüfer Tasci, Gulay Yılmaz, Seda Öner, Pınar Korkmaz, Sevda J Pers Med Article Purpose: Monocyte/HDL cholesterol ratio (MHR) is a novel inflammatory marker that is used as a prognostic factor for cardiovascular diseases and has been studied in many diseases. The aim of this study was to investigate the role of inflammatory factors in schizophrenia patients by examining MHR levels and to compare schizophrenia patients and healthy controls in terms of cardiovascular disease risk. Method: A total of 135 participants between the ages of 18–65, 85 diagnosed with schizophrenia, and 50 healthy individuals in the control group were included in this cross-sectional study. Venous blood samples were taken from the participants and CBC parameters and lipid profiles were analyzed. The sociodemographic and clinical data form and positive and negative symptoms scale (PANSS) were administered to all participants. Results: Although monocyte levels were significantly higher in the patient group, HDL-C levels were lower at significant levels. MHR was found to be higher in the patient group compared to the control group at significant levels. When compared to the control group, total cholesterol, triglyceride, WBC, neutrophil, basophil, and platelet levels were higher in the patient group at significant levels, and RBC, hemoglobin, and hematocrit levels were significantly lower. Conclusion: The elevated MHR in patients with schizophrenia may contribute to our understanding that inflammation plays important roles in the pathophysiology of schizophrenia. Additionally, knowing the levels of MHR and considering the recommendations, such as diet and exercise, in the treatment approaches made us think that it might be beneficial in protecting schizophrenia patients against cardiovascular diseases and early death. MDPI 2023-01-31 /pmc/articles/PMC9958934/ /pubmed/36836510 http://dx.doi.org/10.3390/jpm13020276 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kılıç, Nülüfer
Tasci, Gulay
Yılmaz, Seda
Öner, Pınar
Korkmaz, Sevda
Monocyte/HDL Cholesterol Ratios as a New Inflammatory Marker in Patients with Schizophrenia
title Monocyte/HDL Cholesterol Ratios as a New Inflammatory Marker in Patients with Schizophrenia
title_full Monocyte/HDL Cholesterol Ratios as a New Inflammatory Marker in Patients with Schizophrenia
title_fullStr Monocyte/HDL Cholesterol Ratios as a New Inflammatory Marker in Patients with Schizophrenia
title_full_unstemmed Monocyte/HDL Cholesterol Ratios as a New Inflammatory Marker in Patients with Schizophrenia
title_short Monocyte/HDL Cholesterol Ratios as a New Inflammatory Marker in Patients with Schizophrenia
title_sort monocyte/hdl cholesterol ratios as a new inflammatory marker in patients with schizophrenia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958934/
https://www.ncbi.nlm.nih.gov/pubmed/36836510
http://dx.doi.org/10.3390/jpm13020276
work_keys_str_mv AT kılıcnulufer monocytehdlcholesterolratiosasanewinflammatorymarkerinpatientswithschizophrenia
AT tascigulay monocytehdlcholesterolratiosasanewinflammatorymarkerinpatientswithschizophrenia
AT yılmazseda monocytehdlcholesterolratiosasanewinflammatorymarkerinpatientswithschizophrenia
AT onerpınar monocytehdlcholesterolratiosasanewinflammatorymarkerinpatientswithschizophrenia
AT korkmazsevda monocytehdlcholesterolratiosasanewinflammatorymarkerinpatientswithschizophrenia